Intended Audience: Community-based teams caring for patients with MM, including physicians, PAs/NPs, and nurses specializing in hematology/oncology

A recent quality improvement initiative conducted in community oncology systems revealed common barriers to individualizing multiple myeloma patient care, including lack of documented cytogenetic testing results, low minority enrollment in clinical trials, and suboptimal shared decision-making. In this case-based symposium, multidisciplinary experts in multiple myeloma share findings from the study and strategies to overcome identified barriers, including approaches for incorporating the latest safety and efficacy data into patient care.

Don't miss the opportunity to:

• Apply the lessons learned from this NEW study into your oncology practice
• Hear expert insights on the latest clinical trial data and approaches to individualized treatment planning

If you are in the Atlanta, GA area and would like to attend the live meeting, register here.

• Assess current practice patterns and barriers to evidence-based, equitable, patient-centered care for adults with multiple myeloma (MM)
• Integrate tools and resources to guide personalized treatment decision-making based on clinical and molecular features, current guidelines, and patient goals and preferences
• Evaluate recent research supporting the selection and sequencing of therapy for MM and the role of clinical trial enrollment in facilitating access to novel treatment

1. Disparities in MM Care: Reflecting on Current Barriers to Equitable Care
2. Case-Based Discussions: Practical Approaches to Quality MM Care
1. Supporting Timely Access to Novel Therapies
2. Considerations for Clinical Trial Enrollment
3. Addressing Low Health Literacy, Poor Adherence, and Other Barriers
3. Shared Decision-Making as a Path to Quality MM Care

1. Register using the online form
2. Complete the pre-registration survey
3. Attend the live program in its entirety
4. Complete an online evaluation and post-test
5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

• Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
• Software: the installation of software such as GoToWebinar may be required

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

• Craig Emmitt Cole, MD (Speaker)
  
  Grants / Research Support – GlaxoSmithKline
  Speakers Bureau or other Promotional Education – Oncopeptides, Sanofi
• Sikander Ailawadhi, MD (Speaker)
  
  Advisory Board or Panel – AbbVie, Amgen, Beigene, Janssen, Pharmacyclics
  Consultant – Bristol-Myers Squibb, Oncopeptides, Takeda
  Grants / Research Support – AbbVie, Amgen, Ascentage, Bristol-Myers Squibb, Cellectar, Janssen, Medimmune, Pharmacyclics, TG Therapeutics, Xencor
• Joseph R Mikhael, MD, MEd, FRCPC, FACP (Course Director)
  
  Consultant – Amgen, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi, Takeda
• Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  
  Speakers Bureau or other Promotional Education – Astellas, AstraZeneca, Bristol-Myers Squibb, Coherus, DSI, Dova, Eli Lilly and Company, Gilead Sciences, Morphosys, Pfizer

The following individuals have no relevant financial relationships with commercial interests to disclose:

• Michael R Stinchon, Jr, RPh (Moderator)
• Kathleen A Jarvis, MS, RN, CCM (Reviewer)
• Mark A Rubin, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.